VCRE (Vicore Pharma Holding AB) Total Stockholders Equity: $106.35 Mil (As of Mar. 2026)


VCRE Vicore Pharma Holding AB VCRE
13 GF Score
Price $15.03
! 5 Warning Signs
View Full Analysis

What is Vicore Pharma Holding AB Total Stockholders Equity?

Vicore Pharma Holding AB VCRE -7.54% 13 Total Stockholders Equity is $106.35 Mil as of Mar. 2026. GuruFocus rates VCRE with a GF Score™ of 13/100. The stock has 5 warning signs investors should review.

Vicore Pharma Holding AB's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $106.35 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Vicore Pharma Holding AB's Book Value per Share for the quarter that ended in Mar. 2026 was $0.38. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Vicore Pharma Holding AB's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.00.

Vicore Pharma Holding AB  (NAS:VCRE) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Vicore Pharma Holding AB's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(106.353-0)/281.526
=0.38

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Vicore Pharma Holding AB's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 106.353
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vicore Pharma Holding AB Total Stockholders Equity Related Terms

Vicore Pharma Holding AB Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Vicore Pharma Holding AB's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vicore Pharma Holding AB Total Stockholders Equity Chart

Vicore Pharma Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.17 27.86 44.40 102.81 117.87

Vicore Pharma Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.69 95.12 85.21 117.87 106.35
VCRE
13GF Score
Vicore Pharma Holding AB VCRE
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $106.35 Mil mean?
Vicore Pharma Holding AB (VCRE) has a Total Stockholders Equity of $106.35 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Vicore Pharma Holding AB and its competitors.
Is Vicore Pharma Holding AB's Total Stockholders Equity too high?
Vicore Pharma Holding AB's current Total Stockholders Equity is $106.35 Mil. Overall, Vicore Pharma Holding AB has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Vicore Pharma Holding AB's Total Stockholders Equity compare to ?
Vicore Pharma Holding AB's Total Stockholders Equity of $106.35 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Vicore Pharma Holding AB and its competitors. Vicore Pharma Holding AB's current Total Stockholders Equity is $106.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicore Pharma Holding AB stock overvalued right now?
Vicore Pharma Holding AB (VCRE) has a current Total Stockholders Equity of $106.35 Mil. The current Total Stockholders Equity is $106.35 Mil. Vicore Pharma Holding AB's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Vicore Pharma Holding AB (VCRE), the current Total Stockholders Equity is $106.35 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vicore Pharma Holding AB Business Description

Comparable Companies
Other Exchanges VICO:Sweden6Y4:Germany
Address Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
13GF Score

Get the complete analysis for VCRE

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.03
Price